STAT3 and non-small cell lung carcinoma: Furthermore, Lee et al. identified that STAT3 activation-mediated activation of WNT/β-catenin signaling accounts for the acquired resistance of non-small cell lung cancer cells to the anticancer agent 17-AAG, an Hsp90 inhibitor [56].